


NOTIFICATION PURSUANT TO
SECTION 6 OF DSHEA



In compliance with Section 6 of the Dietary Supplement Health Education Act (DSHEA) and Rule 21 C.F.R. 101.93, this Notification is filed on behalf of the following manufacturer of **Metaform™ Metacuts™ Product #52472** bearing the statements set out below:

3843 '98 APR 14 P2:22
Weider Nutrition International, Inc.
2002 South 5070 West
Salt Lake City, Utah 84104

The text of each structure-function claim for **16.5mg Ephedrine; 170mg Caffeine; 495 mg Hydroxycitrate; 200mcg Chromium; 100mg L-carnitine; 100mg Magnesium; 100mg Quercetin** is as follows:

- | | |
|-----------------------|--|
| (Statement 1) | Pre-exercise and energy booster. |
| (Statement 2) | Thermogenic Blend contains several ephedrine isomers, methylxanthines, bioflavonoid, and other alkaloids. When these compounds are combined, with a sensible diet and exercise program, they encourage a rise in daily energy expenditure and work output. |
| (Statement 3) | Maximum strength caffeine and ephedrine for improved workout and contractile strength, |
| (Statement 4) | Citrimax™ (garcinia cambogia) studies suggest it may have beneficial effects on glycogen utilization for energy. |
| (Statement 5) | Quercetin to increase the duration of the beneficial effects |
| (Statement 6) | Athletes who want better mental focus |
| (Statement 7) | Athletes who want to mobilize body fat and glycogen for energy |
| (Statement 8) | For pre-workout energy |
| (Statement 9) | Midday energy boost |
| (Statement 10) | Thermogenic diet and energy formula |

LET 1478
58110

I, Luke R. Bucci, Ph. D., CCN, CNS, Vice President of Research at Weider Nutrition International, Inc. am authorized to certify this Notification of behalf of the Company. I certify that the information presented and contained in this Notification is complete and accurate and that the Office of Regulatory Affairs at Weider Nutrition International, Inc. has substantiation that each statement is truthful and not misleading.

DATED this 25th day of March, 1998

WEIDER NUTRITION INTERNATIONAL, INC.

BY:

DR. LUKE R. BUCCI

DR. LUKE R. BUCCI

Vice President of Research

STRUCTURE / FUNCTION CLAIMS

NUTR ENT: Ephedrine/ Caffeine/ Hydroxycitrate / Chromium
/ Carnitine / Magnesium / Quercetin

DATE: March 10, 1998
Document Name: sfOI mcut.wpd

BY: Luke R. Bucci, PhD

BRAND, CODE # & PRODUCT NAME(S): Metaform 52472 Metacuts™ 60c

NUTRIENT AMOUNT: 16.5mg ephedrine; 170mg caffeine; 495mg hydroxycitrate; 200mcg chromium; 100mg L-carnitine; 100mg magnesium; 100mg quercetin per serving (4 caps)

STRUCTURE/FUNCTION CLAIM:


Bottle:

- Pre-exercise and energy booster.

METACUTS™ Thermogenic Blend contains several ephedrine isomers, methylxanthines, bioflavonoid, and other alkaloids. When these compounds are combined, with a sensible diet and exercise program, they encourage a rise in daily energy expenditure and work output.

Hang Tag:

- Maximum strength caffeine and ephedrine for improved workout and contractile strength.
- Citrimax™ (Garcinia cambogia) studies suggest it may have beneficial effects on glycogen utilization for energy.
- Quercetin to increase the duration of the beneficial effects.
- Athletes who want better mental focus.
- Athletes who want to mobilize bodyfat and glycogen for energy.
- For Pre-Workout energy.
- Midday energy boost.
- Thermogenic diet and energy formula


Approved by/ Date

REFERENCES:

Combination (ephedrine/caffeine/quercetin/chromium/carnitine/magnesium:

1. Shugarman A. Effect of thermogenic dietary supplements on resting metabolic rate in healthy male and female volunteers. Unpublished Master's thesis, University of Utah, 1998.

Caffeine & Exercise:

1. Clarkson PM. Nutritional ergogenic aids: caffeine. *Int J Sports Nutr* 1993; 3:103-111.
2. Dodd SL, Herb RA, Powers SK. Caffeine and exercise performance. An update. *Sports Med* 1993; 15(1):14-23.
3. Nehlig A, Debry G. Caffeine and sports activity: a review. *Int J Sports Med* 1994; 15(5):215-223.
4. Thoburn R. Caffeine as an ergogenic aid. *Drugs Sports* 1994; 2(4):18-20.
5. Tarnopolsky MA. Caffeine and endurance performance. *Sports Med* 1994; 18:109-125.
6. Spriet LL. Caffeine and performance. *Int J Sports Nutr* 1995; 5: S84-S99.
7. Graham TE, Spriet LL. Caffeine and exercise performance. *Sports Sci Exchange* 1996; 9(1):1-5.
8. **Spiller G**, Ed. *Caffeine* CRC Press, Boca Raton, FL, 1997.
9. Astrup A, Toubro S, Cannon S, Hein P, Breum L, Madsen J. Caffeine: a double-blind, placebo-controlled study of its thermogenic, metabolic, and cardiovascular effects in healthy volunteers. *Am J Clin Nutr* 1985; 51:759-767.

Caffeine & Ephedrine:

1. Dulloo AG, Miller DS. The thermogenic properties of ephedrine/methyloxanthine mixtures: human studies. *Int J Obesity* 1986; 10:467-481.
2. Pasquali R, Cesari MP, Besteghi L, Melchionda N, Balestra V. Thermogenic agents in the treatment of human obesity: preliminary results. *Int J Obesity* 1987; 11 (Suppl 3):23-26.
3. Astrup A, Buemann B, Christensen NJ, Toubro J, Thorbek G, Victor OJ, Quaade F. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. *Metabolism* 1992; 41 (7):686-688.
4. Astrup A, Bruem L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. *Int J Obesity* 1992; 16:269-277.
5. Toubro S, Astrup A, Breum L, Quaade F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. *Int J Obesity* 1993; 17(Suppl 3): S73-S77.
6. Breum L, Pedersen JK, Ahlstrom F, Frimodt-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity. A double-blind multi-centre trial in general practice. *Int J Obesity* 1994; 18:99-102.
7. Horton TJ, Geissler CA. Aspirin potentiates the effect of ephedrine on the thermogenic response to a meal in obese but not lean women. *Int J Obesity* 1991; 15:359-366.
8. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. *Int J Obesity* 1993; 17(Suppl 3):S73-S78.
9. Colker CM, Kalman DS, Minsch A. Ephedrine, caffeine, and aspirin enhance fat loss under nonexercising conditions. *J Am Coll Nutr* 1997; 16(5):501.
10. Krieger DR, Daly PA, Dulloo AG, Ransil BJ, Young JB, Landsberg L. Ephedrine, caffeine and aspirin promote weight loss in obese subjects. *Trans Assoc Am Phys* 1990; 103:306-312.
11. Dulloo AG, Miller DS. Aspirin as a promoter of ephedrine-induced thermogenesis: potential use in the treatment of obesity. *Am J Clin Nutr* 1987; 45:564-569.
12. Dulloo AG. Ephedrine, xanthines and prostaglandin-inhibitors: actions and interactions in the stimulation of thermogenesis. *Int J Obesity* 1993; 17(Suppl 3): S35-S40.
13. Dulloo AG, Seydoux J, Girardier L. Potentiation of the thermogenic antiobesity effects of

ephedrine by dietary methylxanthines: adenosine antagonism or phosphodiesterase inhibition? *Metabolism* 1992; 41(11):1233-1241.

14. Dulloo AG, Miller DS. Ephedrine, caffeine and aspirin: "over-the-counter" drugs that interact to stimulate thermogenesis in the obese. *Nutrition* 1989; 5(1):7-9.

Ephedrine & Exercise:

1. Bucci LR. Dietary supplements as ergogenic aids, Ch 13 in *Nutrition in Exercise and Sport*, Wolinsky 1, Ed., CRC Press, Boca Raton, FL, 1998, 315-346.
2. Jones D, Egger T. Use of herbs containing natural source ephedrine alkaloids in weight loss programmed. *Int J Obesity* 1993; 17(Suppl 3):S81.
3. Pasquali R, Cesari MP, Melchionda N, Stefanini C, Raitano A, Labo G. Does ephedrine promote weight loss in low-energy-adapted obese women? *Int J Obesity* 1987; 11:163-168.
4. Astrup A, Lundsgaard C, Madsen J, Christensen NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. *Am J Clin Nutr* 1985; 42:83-94.
5. Morgan JB, York DA, Wasilewska A, Portman J. A study of the thermic responses to a meal and to a sympathomimetic drug (ephedrine) in relation to energy balance in man. *Br J Nutr* 1982; 47:21-32.
6. Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. *Am J Physiol* 1985; 248: E507-E515.
7. Pasquali R, Baraldi G, Cesari MP, Melchionda N, Zamboni M, Stefanini C, Raitano A. A controlled trial using ephedrine in the treatment of obesity. *Int J Obesity* 1985; 9:93-98.
8. Pasquali R, Casimirri F, Melchionda N, Grossi G, Bortoluzzi L, Morselli Labate AM, Stefanini C, Raitano A. Effects of chronic administration of ephedrine during very-low calorie diets on energy expenditure, protein metabolism and hormone levels in obese subjects. *Clin Sci* 1992; 82:85-92.
9. Malchow-Moller A, Larsen S, Hey H, Stokholm KH, Juhl E, Quaade F. Ephedrine as an anorectic: the story of the 'Elsinore pill'. *Int J Obesity* 1981; 5:183-187.

Hydroxycitrate:

1. Watson JA, Fang M, Lowenstein JM. Tricarbyllate and hydroxycitrate: substrate and inhibitor of ATP:citrate oxaloacetate lyase. *Arch Biochem Biophys* 1969; 135:209-217.
2. Lowenstein JM. Effect of (-)-hydroxycitrate on fatty acid synthesis by rat liver in vivo. *J Biol Chem* 1971; 246:629-632.
3. Sullivan AC, Triscari J. Novel pharmacological approaches to the treatment of obesity, in *Recent Advances in Obesity Research: II. Proceedings of the 2nd International Congress on Obesity*, Bray GA, Ed., Technomic Publishing co., Westport, CT, 1977, 442-452.
4. Hamilton JG, Sullivan AC, Kritchevsky D. Hypolipidemic activity of (-)-hydroxycitrate. *Lipids* 1977; 12(1):1-9.
5. Sullivan AC, Triscari J, Cheng L. Appetite regulation by drugs and endogenous substances, Ch 10 in *Nutrition and Drugs*, Winick M, Ed., John Wiley & Sons, New York, 1983, 139-167.
6. Sullivan AC, Triscari J. Pharmacological approaches to the regulation of metabolism and obesity, in *Recent Advances in Obesity Research. IV. Proceedings of the 4th International Congress on Obesity*, Hirsch J, Van Itallie TB, Eds., John Libbey, London, 1983, 196-207.
7. Sullivan AC, Triscari J, Comai K. Pharmacological modulation of lipid metabolism for the treatment of obesity. *Int J Obesity* 1984; 8(Suppl. 1):241-248.

8. Sergio W. A natural food, the Malabar tamarind, may be effective in the treatment of obesity. *Med Hypotheses* 1988; 27:39-40.
9. McCarty MF. Promotion of hepatic lipid oxidation and gluconeogenesis as a strategy for appetite control, *Med Hypotheses* 1994; 42:215-225.
10. Conte AA. A non-prescription alternative in weight reduction therapy. *The Bariatrician* 1993; Summer:17-19.
11. Conte A. Clinical evaluations of (-)-hydroxycitrate, Ch 6 in *Citrin®. A Revolutionary, Herbs/ Approach to Weight Management*, Majeed M, Rosen R, McCarty M, Conte A, Patil D, Butrym E, Eds., New Editions Publishing, Burlingame, CA, 1994, 52-60,
12. Anonymous, European study cites Citrin as effective for obesity. *Health Foods Business* 1996; June:14.

L-Carnitine:

1. Bucci LR. Micronutrient supplementation and ergogenesis - metabolic intermediates, Ch 4 in *Nutrients as Ergogenic Aids in Sports and Exercise*, CRC Press, Boca Raton, 1993, 47-53,
2. Cerretelli P, Marconi C. L-Carnitine supplementation in humans. The effects on physical performance. *Int J Sports /Wed* 1990; 11(1):1-14.
3. Clarkson PM. Nutritional ergogenic aids: carnitine. *Int J Sport Nutr* 1992; 2:185-190.
4. Cereda G, Scolari M. Effect of an energy stimulator on the performance of a group of young people: evaluation by a video-game test. *Acts Vitaminol Enzymol* 1984; 6(1):63-68.

Chromium:

1. Nielsen FH. Chromium, in *Modern Nutrition in Health and Disease*, 8th cd., Shils ME, Olson JA, Shike M, Eds., Lea & Febiger, Philadelphia, 1994, 264-268.
2. Stoecker BJ. Chromium, in *Present Knowledge in Nutrition*, 6th cd., Brown ML, Ed., International Life Sciences Foundation, Washington, DC, 1990, 287-293.
3. Anderson RA, Polansky MM, Bryden NA, Roginski EE, Mertz W, Glinesmann WH. Chromium supplementation of human subjects: effects on glucose, insulin, and lipid variables. *Metabolism* 1983; 32:894-899.
4. Evans GW. The effect of chromium picolinate on insulin controlled parameters in humans. *Int J Biosocial Med Res* 1989; 11 (2): 163-180.
5. McCarty MF. The case for supplemental chromium and a survey of clinical studies with chromium picolinate. *J Appl Nutr* 1991; 43:58-66.
6. Anderson RA, Cheng N, Bryden N, Polansky M, Cheng N, Chi J, Feng J. Beneficial effects of chromium for people with type II diabetes. *Diabetes* 1996; 45(Suppl 2): 124A.
7. Evans GW, Bowman TD. Chromium picolinate increases membrane fluidity and rate of insulin internalization. *J Inorg Biochem* 1992; 46:243-250.
8. Hasten DL, Rome EP, Franks BD, Hegsted M. Anabolic effects of chromium picolinate on beginning weight training students, *Int J Sport Nutr* 1992; 2:343-350.
9. Evans GW, Pouchnik DJ. Composition and biological activity of chromium-pyridine carboxylate complexes. *J Inorg Biochem* 1993; 49:177-187.
10. Clancy SP, Clarkson PM, DeCheke ME, Nosaka K, Freedson PS, Cunningham JJ, Valentine B. Effects of chromium picolinate supplementation on body composition, strength, and urinary chromium loss in football players. *Int J Sport Nutr* 1994; 4(2):142-153.
11. Hallmark MA, Reynolds TH, DeSouza CA, Dotson CO, Anderson RA, Rogers MA. Effects

- of chromium and resistive training on muscle strength and body composition, *Med Sci Sports Exer* 1996; 28(1):139-144.
12. Kaats GR, Fisher JA, Blum K. The effects of chromium picolinate supplementation on body composition in different age groups. *Age* 1991; 14:138.
 13. Bahadori B, Habersack S, Schneider H, Wascher TC, Toplak H. Treatment with chromium-picolinate improves lean mass in patients following weight reduction. *Int J Obesity* 1995; 19(suppl 2):38.
 14. Kaats GR, Blum K, Fisher JA, Adelman JA. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. *Curr Ther Res* 1996; 57(10):747-756.
 15. Kaats GR, Blum K, Pullin D, Keith SC, Wood R. A randomized double-masked placebo controlled replication and extension of the effects of chromium picolinate supplementation on body composition, *Curr Ther Res* 1998, in press.

Magnesium:

1. **Jaedig S**, Lindgiarde F, Arborelius M. Increased postprandial energy expenditure in obese women after peroral K- and Mg-phosphate. *Miner Electrolyte Metab* 1994; 20(3):147-152.
2. Jaedig S, Henningsen NC. Increased metabolic rate in obese women after ingestion of potassium, magnesium- and phosphate-enriched orange juice or injection of ephedrine. *Int J Obesity* 1991; 15(6):429-436.

Quercetin:

1. Landolfi R, Mower RL, Steiner M. Modification of platelet function and arachidonic acid metabolism by bioflavonoid. Structure-activity relations. *Biochem Pharmacol* 1984; 33(9):1525-1530.
2. Hoffman BB, Chang H, Dall'Aglio E, Reaven GM. Desensitization of adenosine receptor-mediated inhibition of lipolysis. The mechanism involves the development of enhanced cyclic adenosine monophosphate accumulation in tolerant adipocytes. *J Clin Invest* 1986; 78(1):185-190.
3. Lanza F, Berretz A, Stierle A, Corre G, Cazenave JP. Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization. *Thromb Res* 1987; 45(5):477-484.
4. Kuppusamy UR, Das NP. Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes. *Biochem Pharmacol* 1992; 44(7):1307-1315.
5. Kuppusamy UR, Das **NP**. Potentiation of beta-adrenoreceptor **agonist-mediated** lipolysis **by quercetin and** fisetin in isolated rat adipocytes. *Biochem Pharmacol* 1994; 47(3):521-529,